drugset / Trial / NCT03964207

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

NCT03964207

Phase 4 Completed 72 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the superiority of Respimat®.

Timeline

Start
2019-11-25
Primary completion
2021-10-19
Completion
2021-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 5 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled